Arens Ramon, Schepers Koen, Nolte Martijn A, van Oosterwijk Michiel F, van Lier René A W, Schumacher Ton N M, van Oers Marinus H J
Laboratory for Experimental Immunology, Academic Medical Center, University of Amsterdam, Netherlands.
J Exp Med. 2004 Jun 7;199(11):1595-605. doi: 10.1084/jem.20031111.
In vivo priming of antigen-specific CD8+ T cells results in their expansion and differentiation into effector T cells followed by contraction into a memory T cell population that can be maintained for life. Recent evidence suggests that after initial antigenic stimulation, the magnitude and kinetics of the CD8+ T cell response are programmed. However, it is unclear to what extent CD8+ T cell instruction in vivo is modulated by costimulatory signals. Here, we demonstrate that constitutive ligation of the tumor necrosis factor receptor family member CD27 by its ligand CD70 quantitatively augments CD8+ T cell responses to influenza virus infection and EL-4 tumor challenge in vivo by incrementing initial expansion and maintaining higher numbers of antigen-specific T cells in the memory phase. Concomitantly, the quality of antigen-specific T cells improved as evidenced by increased interferon (IFN)-gamma production and a greater cytotoxic potential on a per cell basis. As an apparent consequence, the superior effector T cell formation induced by CD70 protected against a lethal dose of poorly immunogenic EL4 tumor cells in a CD8+ T cell- and IFN-gamma-dependent manner. Thus, CD70 costimulation enhances both the expansion and per cell activity of antigen-specific CD8+ T cells.
体内抗原特异性CD8 + T细胞的致敏导致其扩增并分化为效应T细胞,随后收缩为可终身维持的记忆T细胞群体。最近的证据表明,在初始抗原刺激后,CD8 + T细胞反应的幅度和动力学是预先设定的。然而,尚不清楚体内CD8 + T细胞指令在多大程度上受共刺激信号的调节。在这里,我们证明肿瘤坏死因子受体家族成员CD27通过其配体CD70的组成性连接,通过增加初始扩增并在记忆阶段维持更多数量的抗原特异性T细胞,在体内定量增强CD8 + T细胞对流感病毒感染和EL-4肿瘤攻击的反应。同时,抗原特异性T细胞的质量得到改善,这表现为干扰素(IFN)-γ产生增加以及单个细胞的细胞毒性潜力更大。作为一个明显的结果,CD70诱导的卓越效应T细胞形成以CD8 + T细胞和IFN-γ依赖性方式保护免受致死剂量的低免疫原性EL4肿瘤细胞的侵害。因此,CD70共刺激增强了抗原特异性CD8 + T细胞的扩增和单个细胞活性。
Nat Immunol. 2000-11
Int J Mol Sci. 2025-5-21
Cancers (Basel). 2023-5-11
Clin Transl Med. 2022-12
Nat Rev Immunol. 2003-8
Nat Immunol. 2003-4
J Immunol. 2003-1-1
Annu Rev Immunol. 2003